Citius Oncology, Inc. (CTOR) stock
CTORNasdaqPharmaceutical PreparationsFiscal year ends September 30
$0.56+0.01 (+1.79%)
Close on Nov 18, 2026Market cap $51.83MP/E –Yield –
Citius Oncology net income
Net income is the profit left for shareholders after every expense, interest and tax.
Citius Oncology's net income for the twelve months ending Jun 30, 2026 was -$46.06M. For fiscal 2025 it was -$24.76M, down 6602.3% from the year before.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | -$24.76M | -6602.3% |
| FY2022 | Dec 31, 2022 | $380.81K | – |
Quarterly net income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | -$8.92M | – |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | -$26.61M | – |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | -$5.53M | – |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | -$5.00M | – |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | -$5.37M | – |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | -$7.74M | – |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | -$6.66M | – |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | -$724 | – |
See a number that looks wrong?